Incyte’s Phase II Study for Opzelura Returns Promising Results in Adult Patients
March 11th 2024The company’s twice-daily, branded ruxolitinib cream 1.5% presents a significant reduction in abscess and inflammatory nodule (AN) count for the treatment of Hurley stage 1 or 2 (mild-to-moderate) hidradenitis suppurativa.
Navigating the Current Funding Slowdown While Securing Capital
March 7th 2024In this Pharmaceutical Commerce video interview, Emma Banks, CEO of ramarketing, discusses the biggest roadblocks to the widespread adoption of novel modalities, and how new biotech companies can navigate the current funding slowdown while securing the capital crucial for their success.
How Long Will the Current Slowdown in Biotech Investment Last?
March 6th 2024In this Pharmaceutical Commerce video interview, Emma Banks, CEO of ramarketing, discusses how the balance between onshoring and outsourcing will evolve, how long will the current slowdown in biotech investment likely last, and what factors might influence its duration.